Designing and Developing the Next Generation of Vaccine Adjuvants
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (20 April 2023) | Viewed by 13203
Special Issue Editors
Interests: adjuvants; vaccine development
Special Issue Information
Dear Colleagues,
Over the past two decades, there have been significant advances in the development of novel vaccine adjuvant formulations, building from an improved understanding of how these adjuvants work, and the key role of ‘delivery’. In addition to the established insoluble aluminum salts and emulsion adjuvants, this past decade also saw the advance of several new adjuvants into clinical development, and even included into licensed products. These recent advances have expanded our understanding on mechanisms of action and have laid the groundwork for the development of new and improved technologies. There have been significant insights into the identification of new and improved agonists, which can be exploited for the rational development of the next generation of adjuvants—particularly if these ligands can be coupled with improved delivery systems to enhance potency, and limit reactogenicity, or safety concerns. This Special Issue on “Designing and Developing the Next Generation of Vaccine Adjuvants” will focus on highlighting key tools for designing and discovering novel vaccine adjuvants as well as discussing advances made in developing adjuvants suitable for clinical evaluation.
Dr. Derek T. O'Hagan
Dr. Rushit N. Lodaya
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adjuvant systems
- immune potentiators
- immunomodulators
- toll-like receptor (TLR) agonists
- emulsions
- aluminum salts
- nanoparticles
- polymers